The fact that ZNF224 expression in CLL patients is associated with BCL2/BAX ratios higher than 1 (Supplementary Figure.S3), as well as with high MCL1 levels (Figure 3), strengthens its proposed oncogenic role and predictive potential as a marker/indicator of aggressiveness and poor prognosis. Here, ZNF224 is linked to B-cell chronic lymphocytic leukemia.